Efinaconazole-containing composition

A stable and environmentally friendly efinaconazole composition is achieved by incorporating a chelating agent and antioxidant, addressing heat and light instability and skin irritation issues.

JP2024158211AInactive Publication Date: 2024-11-08TOA PHARMA
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023073212
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-04-27
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Efinaconazole is unstable to heat and light, leading to discoloration during storage, and formulations containing decamethylcyclopentasiloxane raise environmental concerns.

Method used

A composition containing efinaconazole, a chelating agent, and an antioxidant, without decamethylcyclopentasiloxane, with specific concentration ratios to enhance stability and reduce skin irritation.

Benefits of technology

The composition achieves improved thermal and photostability of efinaconazole with reduced skin irritation, meeting environmental standards.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024158211000007
    Figure 2024158211000007
  • Figure 2024158211000001
    Figure 2024158211000001
  • Figure 2024158211000002
    Figure 2024158211000002
Patent Text Reader

Abstract

To provide an efinaconazole-containing composition that is highly stable and friendly to the environment.SOLUTION: The present invention provides a composition that contains efinaconazole, a chelator and an antioxidant and is free of decamethylcyclopentasiloxane. Relative to the mass of the entire composition, the concentration content of the antioxidant is less than 1.0 mass%.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to compositions containing efinaconazole. [Background technology]

[0002] Efinaconazole (chemical name: (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol) is known as a type of azole antifungal drug. In Japan, Clenafin (registered trademark) nail solution containing efinaconazole as an active ingredient has been approved as a treatment for onychomycosis (Non-Patent Document 1).

[0003] Efinaconazole is known to have a problem that it is unstable to heat and light and is prone to discoloration during storage. In response to this problem, several formulation techniques have been reported that suppress discoloration of efinaconazole by compounding it with specific additives and formulating it. For example, Patent Document 1 describes an invention relating to a composition that contains efinaconazole, ethanol, water, butylated hydroxytoluene (BHT), and a salt of ethylenediaminetetraacetic acid (EDTA) at specific concentrations, which is colorless when formulated and colorless or pale yellow after storage at a temperature of about 40° C. for at least three weeks. Patent Document 2 describes an invention relating to a formulation that contains efinaconazole, a specific non-volatile ester, a pH adjuster, and an antioxidant, and is substantially free of ethylenediaminetetraacetic acid.

[0004] On the other hand, nail external preparations are required to have a certain level of nail permeability, and additives are formulated to enhance nail permeability. The nail external solution described in Non-Patent Document 1 contains ethanol, decamethylcyclopentasiloxane, diisopropyl adipate, alkyl lactate, etc. as additives. Among these additives, decamethylcyclopentasiloxane is a type of cyclic silicone compound, and is known as a solvent for oily components that are commonly used for the purpose of providing a good spreadability and non-viscous feel to make it easy to apply.

[0005] On the other hand, decamethylcyclopentasiloxane is a candidate for a substance of very high concern under the European Chemicals Regulation (REACH: Registration, Evaluation, Authorization and Restriction of Chemicals) due to concerns about its biological effects in water systems (Non-Patent Document 2). In Europe, the sale of products that contain decamethylcyclopentasiloxane at or above a certain concentration and that are washed off with water after use is prohibited (Non-Patent Document 2). [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Patent No. 6774518 [Patent Document 2] International Publication No. 2021 / 132348 [Non-patent literature]

[0007] [Non-Patent Document 1] Clenafin(R) Nail Topical Solution 10% Pharmaceutical Interview Form [Non-Patent Document 2] ECHA (EUROPEAN CHEMICAL AGENCY) ANNEX XVII TO REACH - Conditions of restriction, Entry 70 Summary of the Invention [Problem to be solved by the invention]

[0008] Patent Documents 1 and 2 describe the formulation of additives for suppressing discoloration of efinaconazole-containing preparations, but these do not completely suppress discoloration of efinaconazole due to heat. Therefore, a technology for further improving the stability of efinaconazole is required. In addition, Non-Patent Document 2 describes concerns about the biological effects of decamethylcyclopentasiloxane in aqueous systems, so a formulation that does not contain decamethylcyclopentasiloxane is desired from the viewpoint of the environment, etc.

[0009] An object of the present invention is to provide an efinaconazole-containing composition which is excellent in stability and is environmentally friendly. [Means for solving the problem]

[0010] Means of the Invention The present inventors have conducted intensive studies to solve the above problems and have found that the stability of efinaconazole can be improved by incorporating a chelating agent and an antioxidant into an efinaconazole-containing composition.

[0011] Furthermore, the present inventors have unexpectedly found that by eliminating decamethylcyclopentasiloxane from an efinaconazole-containing composition, skin irritation is reduced.

[0012] Based on the above findings, the present inventors have completed the present invention.

[0013] That is, the present invention relates to the following. [1] A composition comprising efinaconazole, a chelating agent and an antioxidant, but not containing decamethylcyclopentasiloxane, wherein the concentration of the antioxidant relative to the total mass of the composition is less than 1.0 mass%. [2] The composition described in [1], wherein the chelating agent is edetic acid, an edetate salt, or a hydrate of edetic acid or an edetate salt. [3] The composition described in [1] or [2], wherein the chelating agent is sodium edetate hydrate. [4] The composition according to any one of [1] to [3], wherein the antioxidant is one or more selected from dibutylhydroxytoluene (BHT) and butylhydroxyanisole (BHA). [5] The composition described in any one of [1] to [4], wherein the antioxidant is BHA. [6] The composition according to any one of [1] to [5], wherein the concentration of the antioxidant relative to the total mass of the composition is 0.1 mass % or more and less than 1.0 mass %. [7] The composition described in any one of [1] to [6], wherein the ratio of the antioxidant concentration to the efinaconazole concentration in the entire composition (antioxidant concentration (mass %) / efinaconazole concentration (mass %)) is 0.01 to 0.1. [8] The composition according to any one of [1] to [7], further comprising a pH adjuster. [9] The composition according to any one of [1] to [8], wherein when stored for 3 weeks at 60°C under light-shielded conditions, the ratio of the absorbance at 400 nm after storage to the absorbance at 400 nm at the start of storage (absorbance at 400 nm (Abs.) after storage / absorbance at 400 nm (Abs.) at the start of storage) is 2.0 or less.

[10] The composition described in any one of [1] to [9] for use in the treatment of onychomycosis. Effect of the Invention

[0014] According to the present invention, there is provided an efinaconazole-containing composition which is excellent in stability and has reduced skin irritation. [Brief description of the drawings]

[0015] [Figure 1] FIG. 1 shows the results of a permeability test using a human nail model. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] (composition) The present invention relates to an efinaconazole-containing composition. The composition of the present invention is intended to be applied directly to specific parts of the body, in particular to the skin, mucous membranes, nails, etc., and is preferably intended to be applied to the nails.

[0017] The composition of the present invention contains efinaconazole as an active ingredient. The concentration of efinaconazole in the composition of the present invention is not particularly limited, but is preferably 5 to 15 mass %, more preferably 8 to 12 mass %, and particularly preferably 10 mass %, based on the mass of the entire composition.

[0018] The composition of the present invention may contain one or more chelating agents. Examples of the chelating agent include edetic acid, edetate, hydroxyethylethylenediaminetriacetic acid (HEDTA), diethylenetriaminepentaacetic acid (DTPA), nitrilotriacetic acid (NTA), triethylenetetraminehexaacetic acid (TTHA), glycoletherdiaminetetraacetic acid (GEDTA), and hydrates thereof. In a preferred embodiment, the composition of the present invention contains edetate.

[0019] The concentration of the chelating agent in the composition of the present invention is preferably 0.00005 to 0.001% by mass, more preferably 0.0001 to 0.0005% by mass, even more preferably 0.0002 to 0.0003% by mass, and particularly preferably 0.00025% by mass, based on the total mass of the composition. The ratio of the concentration of the chelating agent to the concentration of efinaconazole in the total composition of the present invention (concentration of the chelating agent (% by mass) / concentration of efinaconazole (% by mass)) is preferably 0.000005 to 0.0001, more preferably 0.00001 to 0.00005, even more preferably 0.00002 to 0.00003, and particularly preferably 0.000025.

[0020] The composition of the present invention may contain one or more antioxidants. In the present invention, the term "antioxidant" refers to a so-called reducing antioxidant that is more easily oxidized than the active ingredient and reduces substances involved in oxidation, and does not include a so-called chelating agent that inhibits the action of metal ions as a catalyst for oxidation reactions. The reducing antioxidant may include a hydrophilic antioxidant and a lipophilic antioxidant. Examples of the hydrophilic antioxidant include dry sodium sulfate, sodium sulfite, sodium pyrosulfite, sodium thiosulfate, ascorbic acid, etc. Examples of the lipophilic antioxidant include dibutylhydroxytoluene (BHT), butylhydroxyanisole (BHA), tocopherol, propyl gallate, etc. In a preferred embodiment, the composition of the present invention contains one or more lipophilic antioxidants. In a more preferred embodiment, the composition of the present invention contains one or more selected from BHT and BHA. Particularly preferably, the composition of the present invention contains BHA.

[0021] The concentration of the antioxidant in the composition of the present invention is preferably 0.01% by mass or more and less than 1.0% by mass, more preferably 0.05 to 0.9% by mass, even more preferably 0.1 to 0.8% by mass, particularly preferably 0.1 to 0.5% by mass, and most preferably 0.1 to 0.2% by mass, based on the mass of the entire composition. The ratio of the concentration of the antioxidant to the concentration of efinaconazole in the entire composition of the present invention (concentration of antioxidant (mass%) / concentration of efinaconazole (mass%)) is preferably 0.001 to 0.1 and less than 0.1, more preferably 0.005 to 0.09, more preferably 0.01 to 0.08, particularly preferably 0.01 to 0.05, and most preferably 0.01 to 0.02.

[0022] The composition of the present invention does not contain decamethylcyclopentasiloxane. Decamethylcyclopentasiloxane is sometimes written as cyclomethicone in cosmetic labeling names, etc. "Does not contain decamethylcyclopentasiloxane" does not only mean that decamethylcyclopentasiloxane is not contained at all, but also that decamethylcyclopentasiloxane is substantially not contained. "Does not substantially contain decamethylcyclopentasiloxane" includes the inclusion of decamethylcyclopentasiloxane to an extent that does not inhibit the effect of the present invention.

[0023] The composition of the present invention may contain one or more pH adjusters to enhance stability and nail permeability. The pH adjuster is not particularly limited as long as it is known to those skilled in the art, and may be, for example, citric acid, citrate salts, acetic acid, acetate salts, phosphoric acid, phosphate salts, lactic acid, lactate salts, tartaric acid, tartrate salts, malic acid, malate salts, hydrochloric acid, or anhydrides thereof. Preferably, the composition of the present invention contains anhydrous citric acid.

[0024] In one embodiment, the composition of the present invention is prepared by dissolving efinaconazole and each additive in a solvent. The solvent used is not particularly limited as long as it can dissolve efinaconazole and other additives, and may be, for example, one or more selected from polar solvents and non-polar solvents. One or more polar solvents and one or more non-polar solvents may be used in combination. As the polar solvent, for example, propylene glycol, glycerin, ethanol, water, etc. can be used, and preferably one or more of water and ethanol are used. As the water, for example, it is not particularly limited, and for example, distilled water, ordinary water, purified water, sterilized purified water, water for injection, etc. can be used, and preferably purified water can be used. As the non-polar solvent, for example, one or more of alkyl lactate and diisopropyl adipate can be used. Alkyl lactate is a compound in which lactic acid and aliphatic alcohol are ester-bonded. The aliphatic alcohol has a linear or branched alkyl group, and the number of carbon atoms in the alkyl group may be any number, for example, 4 to 6, 12 to 13, 12 to 14, 12 to 15, etc., and preferably 12 to 15. In this specification, for example, an alkyl lactate having an alkyl group with 12 to 15 carbon atoms may be described as C12-15 alkyl lactate, alkyl lactate (C12-15), etc.

[0025] The composition of the present invention may further contain one or more other additives within a range that does not impair the effects of the present invention. Examples of other additives include surfactants (emulsifiers), preservatives (antiseptics), and other known additives such as thickeners, ultraviolet absorbers, fragrances, cooling agents, and odorants.

[0026] The composition of the present invention can be produced by a known production method. For example, after dissolving an antioxidant and a chelating agent in a solvent, efinaconazole is added and dissolved. The solution is adjusted to a constant volume using the above-mentioned solvent to prepare an efinaconazole-containing composition. If necessary, it may be appropriately filtered.

[0027] (thermal stability) The composition of the present invention can improve the thermal stability of efinaconazole. The thermal stability can be evaluated, for example, by measuring the coloration or discoloration of the composition at the start of storage and after storage when the efinaconazole-containing composition is stored for a predetermined period under a predetermined temperature condition, and comparing the two. If the change in coloration after storage is small compared to the start of storage, the thermal stability can be evaluated as high. The temperature condition for storage can be, for example, 30°C or higher, 40°C or higher, 50°C or higher, 60°C or higher, or 70°C or higher, and may or may not be constant during the storage period. The temperature condition for storage can be preferably 60°C and constant during the storage period. Storage can be performed under light-shielded conditions or under open conditions. The storage period can be, for example, 1 day or more, 3 days or more, 5 days or more, 1 week or more, 2 weeks or more, 3 weeks or more, 4 weeks or more, and preferably 3 weeks.

[0028] The coloration of the efinacozole-containing composition can be evaluated, for example, by measuring the absorbance, measuring the color difference, and specifying the color perception of the composition. The absorbance may be measured by a method known to those skilled in the art, for example, using an absorptiometer such as a spectrophotometer. The wavelength for measuring the absorbance of the composition of the present invention may be, for example, 400 to 600 nm, and preferably 400 nm. The color difference may be measured, for example, using a color difference meter. The color perception may be scaled and specified according to the three attributes of color perception (hue, brightness, saturation) in JIS Z 8721-1993 "Method of displaying color-display by three attributes". Note that the appearance change due to obvious coloring or discoloration of the efinacozole-containing composition may be judged by visual inspection, observation, etc.

[0029] In the composition of the present invention, when stored at 60° C. under light-shielded conditions for 3 weeks, the ratio of the absorbance at 400 nm after storage to the absorbance at 400 nm at the start of storage (absorbance at 400 nm after storage (Abs.) / absorbance at 400 nm at the start of storage (Abs.)) is preferably 2.0 or less, more preferably 1.5 or less, even more preferably 1.2 or less, and particularly preferably 1.0 or less. In addition, in the composition of the present invention, when stored at 60° C. under light-shielded conditions for 3 weeks, the absorbance at 400 nm (Abs.) may be, for example, 0.0600 Abs. or less or 0.0500 Abs. or less, preferably 0.0400 Abs. or less, more preferably 0.0397 Abs. or less, even more preferably 0.0350 Abs. or less, and even more preferably 0.0342 Abs. or less.

[0030] (Photostability) The composition of the present invention can improve the photostability of efinaconazole. The photostability can be evaluated, for example, by performing a light exposure test and measuring changes in physical properties (color tone, appearance such as clarity, dissolution state, etc.) after exposure, the amount of photodegradation products or remaining components, etc. The light exposure is performed, for example, by irradiating the test subject with an accumulated exposure of 300,000 to 1,200,000 lx·hr. The light source used for irradiation is not particularly limited, and D65, which is the standard for outdoor daylight defined by the International Commission on Illumination, or ID65, which is the equivalent standard for indirect daylight indoors, can be used. In addition to these, a white fluorescent lamp showing an output similar to ISO10977 (1993) and a near-ultraviolet fluorescent lamp having a spectral distribution at 320 to 400 nm and a maximum of radiant energy at 350 to 370 nm may be used, and the light source used for irradiation can be appropriately selected by those skilled in the art. The accumulated exposure is the cumulative amount of exposure irradiated per unit time, and is expressed, for example, as "lx·hr" or "W·h / m 2 "lx·hr" represents the total amount of radiation (lx) per unit of time (hr), and "W·h / m 2 " represents the total near-ultraviolet radiant energy per unit time and unit area.

[0031] In one embodiment of the composition of the present invention, the remaining rate of efinaconazole after irradiation with an accumulated irradiation dose of 600,000 lx·hr is preferably 98.5% or more, more preferably 98.8% or more, and even more preferably 99.2% or more.

[0032] (Skin irritation) When applying an external nail solution to a nail, the solution comes into contact with the skin around the nail, so it is desirable that the skin irritation is small. According to the present invention, the skin irritation caused by an efinaconazole-containing composition can be improved. Skin irritation can be evaluated, for example, by the test method described in the Organisation for Economic Development (OECD) Guideline for Testing of Chemicals TG404 (acute skin irritation / corrosion) or a method equivalent thereto, but the evaluation method is not particularly limited thereto. The improvement of skin irritation means that, for example, the value of the primary skin irritation index (PII) shown below is 3.1 or less, preferably 3.0 or less, more preferably 2.5 or less, even more preferably 2.0 or less, and particularly preferably 1.7 or less in the treated skin.

[0033] PII is calculated using the score of the skin reaction according to the Draize criteria described in the above guideline TG404 on the skin at a predetermined time after the treatment. In this case, the skin reaction may be scored at any time after the treatment, for example, 3 hours to 13 days after the treatment, and preferably 3 to 48 hours after the treatment. In addition, the site of the skin where the skin reaction is scored in this case may be one or more sites, and may be healthy skin, damaged skin, or both healthy skin and damaged skin. As the skin damage, it is preferable to scratch the stratum corneum without scratching the dermis. As an example, PII can be calculated by averaging the average scores of erythema / eschar formation and edema formation according to the Draize criteria in healthy skin and damaged skin (stratum corneum scratched without scratching the dermis) 3 and 48 hours after the treatment, i.e., 3 and 48 hours after the sample is no longer applied to the skin, as shown in the examples of the present specification. Draize's criteria are shown below.

[0034] Draize's Standards <Erythema / eschar formation> 0: No erythema 1: Very slight erythema (barely noticeable) 2: Obvious erythema 3: Moderate to severe erythema 4: Deep red erythema with slight crusting (injury is deep)

[0035] <Edema formation> 0: No edema 1: Very mild edema (barely noticeable) 2: Mild edema (clearly distinguishable from surrounding area) 3: Moderate edema (about 1 mm raised) 4: Severe edema (swelling of 1 mm or more, spreading to surrounding areas)

[0036] (Dosage form, efficacy) The composition of the present invention includes solutions, lotions, ointments, creams, etc., but in a preferred embodiment, the composition of the present invention is a solution, i.e., a liquid agent. Particularly preferably, the composition of the present invention is a nail external solution, i.e., a liquid agent to be applied to the nail.

[0037] The composition of the present invention is useful for treating onychomycosis. Onychomycosis is classified into several disease types depending on the invasion route of the causative fungus, and the composition of the present invention can be effective against any type of onychomycosis. EXAMPLES

[0038] The present invention will be described in more detail below by way of examples, but the present invention should not be construed as being limited thereto.

[0039] Preparation of test substances Each test substance was prepared so as to have the composition shown in Table 1. Specifically, each additive other than efinaconazole was mixed and dissolved, then efinaconazole was added and dissolved, and the volume was adjusted to the required volume with ethanol to prepare the test substance.

[0040] [Table 1]

[0041] Test Example 1. Coloring evaluation (thermal stability test) <Test Method> 4 mL of the prepared solution was placed in a transparent glass container and stored at 60° C. (under light-shielded conditions). The UV-visible absorption spectrum was measured before and after 3 weeks of storage using a UV-visible spectrophotometer (UV-2450, Shimadzu Corporation), and the absorbance value at 400 nm was recorded.

[0042] <Test Results> The results are shown in Table 2. The test substances of Comparative Examples 1 and 2, which contained no antioxidant but a chelating agent, and Comparative Example 5, which contained an antioxidant but no chelating agent, were colored faintly yellow. In contrast, when an antioxidant and a chelating agent were contained, coloring was suppressed, indicating that the thermal stability of efinaconazole was improved.

[0043] [Table 2]

[0044] Test Example 2. Photostability test <Test Method> 4 mL of the test substance solution prepared based on the compositions of Comparative Examples 3, 4, and 5 and Examples 3 and 4 in Table 1 was placed in a transparent glass container, and irradiated with a D65 fluorescent lamp as a light source at 25°C to an accumulated irradiation amount of 600,000 lx·hr using a photostability tester (LTL-200A-15WCD, Nagano Science Co., Ltd.). After that, the efinaconazole concentration before and after light irradiation was quantified using a UV spectrophotometer (measurement wavelength: 260 nm) by high performance liquid chromatography. The efinaconazole remaining rate (%) was calculated from the quantified efinaconazole concentration according to the following formula.

[0045] Efinaconazole remaining rate (%) = (Efinaconazole concentration after light irradiation) / (Efinaconazole concentration before light irradiation) × 100

[0046] <Test Results> The results are shown in Table 3. Compared with Comparative Example 5, which contained an antioxidant but no chelating agent, it was shown that the photostability of efinaconazole was improved when a chelating agent and an antioxidant were contained, and particularly, the photostability of efinaconazole was high in the test substances of Examples 3 and 4.

[0047] [Table 3]

[0048] Test Example 3. Primary skin irritation test <Test Method> The hair on the backs of three acclimatized rabbits (female, Kbs:JW) was removed using clippers, and two healthy skin areas and two damaged skin areas (the stratum corneum was abraded with an 18G injection needle, taking care not to damage the dermis) were created as administration sites, for a total of four. Each administration sample (10% formulation of Clenafin (registered trademark) nail external solution as the test substance of Example 3 or the control substance) was soaked in 0.5 mL of lint cloth and applied to the administration site, and the application was occluded for 24 hours using an impermeable adhesive bandage (Blendarm, 3M). To further improve adhesion, the area was fixed using an adhesive sponge bandage and an adhesive elastic bandage. Skin reactions were assessed according to the Draize criteria 3, 24, 48, and 72 hours and 4 to 13 days after removal of the patch, and the average scores for erythema / eschar formation and edema formation 3 and 48 hours after removal of the patch were calculated and summed to represent the reaction intensity. The average of the reaction intensities in the healthy and damaged skin areas was used as the primary irritation index (PII) to evaluate irritation.

[0049] The criteria for judging skin reactions according to the Draize method were based on the following symptoms:

[0050] <Erythema / eschar formation> 0: No erythema 1: Very slight erythema (barely noticeable) 2: Obvious erythema 3: Moderate to severe erythema 4: Deep red erythema with slight crusting (injury is deep)

[0051] <Edema formation> 0: No edema 1: Very mild edema (barely noticeable) 2: Mild edema (clearly distinguishable from surrounding area) 3: Moderate edema (about 1 mm raised) 4: Severe edema (swelling of 1 mm or more, spreading to surrounding areas)

[0052] The composition of Clenafin (registered trademark) nail external solution used as a control substance is shown below (from Non-Patent Document 1). [Table 4]

[0053] <Test Results> For both the test and control substances, skin reactions were observed 3 hours after removal of the patch in healthy skin (n = 3 for each dose group) and damaged skin (n = 3 for each dose group), and as the skin reactions remained even 72 hours after removal of the patch, the observation period was extended and the skin reactions disappeared 6 days after removal of the test substance and 12 days after removal of the control substance. The PII was calculated to be 1.7 for the test substance and 3.2 for the control substance, and the evaluation category was "weak irritant" and "moderate irritant" for the test substance and the control substance, respectively (Table 5).

[0054] [Table 5]

[0055] Therefore, since the skin irritation of the test substance was milder than that of the control substance, the test substance is a preparation with improved irritation properties.

[0056] Test Example 4. Permeability test using a human nail model <Test Method> The human nails used were fingernails (index, middle, and ring finger nails) from Caucasian males, age: 46 to 61 years old. The human nails were sandwiched between Franz cells, phosphate buffered saline containing 40% polyethylene glycol 400 (PEG400-containing PBS) was placed on the receiver side, and 2 μL of the test substance (Example 3) or control substance (Clenafin (registered trademark) nail external solution 10% formulation) was placed on the donor side. The PEG400-containing PBS on the receiver side was sampled over time, and the amount of permeated efinaconazole was measured by high performance liquid chromatography-mass spectrometry.

[0057] <Test Results> As shown in FIG. 1 and Table 6, the cumulative amount of permeation (Q) of the test substance (Example 3) into the nail after 14 days was 3.68±1.56 μg / cm 2 , and the steady-state permeation rate was 0.46±0.19 μg / cm 2 / day, and the lag time (time until the drug permeation into the nail reaches a steady state) was 5.91 ± 0.75 days. On the other hand, the cumulative permeation amount into the nail after 14 days for the control substance (Clenafin®) was 3.76 ± 1.21 μg / cm 2 , with a steady-state permeation rate of 0.47±0.17 μg / cm 2 / day, with a lag time of 5.81±0.44 days.

[0058] [Table 6]

[0059] The results showed that the test substance exhibited good nail permeability comparable to that of the control substance.

Claims

1. 1. A composition comprising efinaconazole, a chelating agent, and an antioxidant, and free of decamethylcyclopentasiloxane, A composition, wherein the concentration of the antioxidant relative to the mass of the entire composition is less than 1.0 mass%.

2. 2. The composition of claim 1, wherein the chelating agent is edetic acid, an edetate salt, or a hydrate of edetic acid or an edetate salt.

3. 3. The composition of claim 1 or 2, wherein the chelating agent is sodium edetate hydrate.

4. 2. The composition of claim 1, wherein the antioxidant is one or more selected from dibutylhydroxytoluene (BHT) and butylhydroxyanisole (BHA).

5. 5. The composition of claim 1 or 4, wherein the antioxidant is BHA.

6. The composition according to claim 1, wherein the ratio of the antioxidant concentration to the efinaconazole concentration in the entire composition (antioxidant concentration (mass %) / efinaconazole concentration (mass %)) is 0.01 to 0.

1.

7. The composition of claim 1 further comprising a pH adjuster.

8. 2. The composition according to claim 1, wherein when stored for 3 weeks at 60° C. under light-shielded conditions, the ratio of the absorbance at 400 nm after storage to the absorbance at 400 nm at the start of storage (absorbance at 400 nm (Abs.) after storage / absorbance at 400 nm (Abs.) at the start of storage) is 2.0 or less.

9. 2. The composition of claim 1 for use in the treatment of onychomycosis.

Citation Information

Patent Citations

  • Stabilized efinaconazole composition

    JP6774518B2

  • Drug containing efinaconazole

    WO2021132348A1